FordePMChaftJESmithKNet al.Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med2018; 378: 1976–1986.
2.
ArmandPEngertAYounesAet al.Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol2018; 36: 1428–1439.
3.
WolchokJDHoosAO’DaySet al.Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res2009; 15: 7412–7420.
4.
HodiFSBallingerMLyonsBet al.Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol2018; 36: 850–858.
5.
ChesonBDFisherRIBarringtonSFet al.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol2014; 32: 3059–3068.
6.
ChesonBDAnsellSSchwartzLet al.Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood2016; 128: 2489–2496.
7.
YounesAHildenPCoiffierBet al.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol2017; 28: 1436–1447.
8.
DadaR. Is our future our past? Response to: refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood2016; 128: 2489–2496. (e-letter).
9.
SubrahmanyamPBDongZGusenleitnerDet al.Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer2018; 6: 18–18.
